Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This research study is studying a novel type of FL vaccine as a possible treatment for
follicular lymphoma (FL).
The agents involved in this study are:
- Rituximab
- Personalized NeoAntigen vaccine
- Poly-ICLC
- Pembrolizumab